After a 6-day court trial, the Federal Trade Commission successfully blocked Edwards Lifesciences from buying JenaValve over ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down. Researchers are now unraveling how these medications affect immune ...

Use of sodium-glucose cotransporter-2 inhibitor (SGLT2) drugs should continue in patients with diabetes, in line with current recommendations, conclude the American Association of Clinical ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may ...

A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

SaveHealth reports on managing type 2 diabetes through medications, lifestyle changes, and support, highlighting various treatment options, side effects, and newer therapies.

A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...